GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything

The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.

Read More

Remote Relief: How Virtual Support Boosts Mood and Confidence for Families Facing Dementia

Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.

Read More

Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science

When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.

HealthTech, Dementia Diagnostics, NIH Corey Hubbafd HealthTech, Dementia Diagnostics, NIH Corey Hubbafd

The Missing Link in Alzheimer’s: How a Natural Brain Element Could Be the Key to Reversing Memory Loss

For over thirty years, Bruce Yankner has been at the very forefront of Alzheimer's research. From his early days first proving the devastating toxicity of amyloid plaques in the 1990s, to his current work uncovering the brain's hidden reliance on natural lithium, his scientific journey has been nothing short of remarkable. By finally explaining the elusive missing link

Read More

Beyond the Memory Trap: Simple Blood Tests, Subcut Injections, and Smart Care Tech are Rewriting the Alzheimer’s Story

Explore the latest 2026 Alzheimer’s research updates. Discover how simple blood tests, new home-injection trials, AI healthtech, and modern caregiving strategies are transforming memory care and hospice support.

Read More

Beyond the "Black Box": Why Trust is the Ultimate Data Moat in Clinical Trial Recruitment

In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy. At Glassbury, we recognize that a "black box" approach is insufficient for the long-term challenges of Alzheimer's disease and related CNS conditions

Read More

The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early

For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors

Read More

Why We Can't Sleep in Early Alzheimer's: The New Science of Brain Inflammation

For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain.

Read More

Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind

There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.

Read More

Lecanemab Real-World Safety: Duke Health Study Insights for Alzheimer’s Patients

For decades, the search for a way to slow down Alzheimer’s disease felt like chasing a horizon that never got closer. However, the arrival of anti-amyloid therapies like lecanemab has shifted the conversation from "what if" to "how." While clinical trials provide a controlled environment to test these drugs

Read More
Big Pharma, Therapuetics, FDA Compliance, NIH Corey Hubbafd Big Pharma, Therapuetics, FDA Compliance, NIH Corey Hubbafd

Tiny Bubbles, Big Breakthrough: How Exosomes Carry Alzheimer's Treatments Past the Blood–Brain Barrier

Your brain consumes roughly 20% of your body's energy, meaning it relies on a massive network of blood vessels. To protect your central nervous system from harmful chemical swings and infections, the cells lining these blood vessels fit together like microscopic puzzle pieces sealed with airtight biological glue. This tight network is the Blood–Brain Barrier.

Read More

A New Era in Alzheimer's Research: Moving Beyond Amyloid

For decades, the public conversation surrounding Alzheimer’s disease focused almost exclusively on a single culprit: sticky protein deposits in the brain known as amyloid-beta plaques. The dominant theory held that if medicine could simply scrub these plaques away, memory loss and cognitive decline could be halted.

Read More